Close Menu

cervical cancer

This story has been updated from a previous version to clarify comments regarding the Aptima HPV test specificity.
By Ben Butkus

The device, named the Verisante Aura, uses Raman spectroscopy to measure levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions. In initial clinical trials it distinguished between benign and malignant lesions with 100-percent sensitivity and 70-percent specificity.

The assay may provide insight into the relationships between various HPV types and their associated diseases — not just cervical cancer, but also potentially head and neck cancers and HPV-associated warts.

Roche presents data from HPV Dx trial; Epigenomics launches Epi proLung BL Reflex Assay in Europe.

Incell's HPV test will be run on Accuri's cytometer as a cervical cancer screening tool.

Enzo Clinical Labs will market the cervical cancer test in New York and New Jersey.

Using gene dosage, expression, and ontology data, the researchers identified recurrent changes linked to cervical cancer development and treatment outcomes.

After comparing results from Qiagen's HPV DNA test with cytology-based screening in more than 100,000 women, the researchers concluded that the HPV test is more sensitive, though its specificity varied by age group.


The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.